Clinical Trials Browser

Phase 2 × Dasatinib × CNS × Clear all

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02559778 2026-02-20

PEDS-PLAN

Phase 2 Recruiting

Neuroblastoma

NCT03352427 2022-10-05

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

Phase 2 Terminated

3 enrolled 7 charts

Glioma, Brain Stem Neoplasms

NCT01467986 2020-10-06

RIST-rNB-2011

Phase 2 Completed

Neuroblastoma

NCT00892177 2019-10-21

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme

Phase 2 Completed

144 enrolled 14 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00423735 2019-07-24

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase 2 Completed

64 enrolled 12 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT02233049 2018-07-23

BIOMEDE

Phase 2 Unknown

Diffuse Intrinsic Pontine Glioma